(Q36427613)

14 August 2017

1 reference

title

Venous thromboembolism risk and management in women with cancer and thrombophilia (English)

1 reference

14 August 2017

1 reference

venous thromboembolism

1 reference

Paolo Prandoni

1

1 reference

14 August 2017

publication date

1 January 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

2 Suppl A

1 reference

14 August 2017

page(s)

S28-34

1 reference

Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Hemostatic alterations in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Hypercoagulability in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Thrombophlebitis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Venous thromboembolism and cancer: new issues for an old topic.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Deep vein thrombosis in cancer: the scale of the problem and approaches to management

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Outcomes and cost of deep venous thrombosis among patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Ovarian cancer and venous thromboembolic risk

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Cancer and venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Inherited thrombophilia and gestational venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

The molecular genetics of familial venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Thrombophilia: an expanding group of genetic defects that predispose to thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Anticoagulants in the treatment of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Risk of venous thromboembolic disease in women A qualitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

The clinical course of deep vein thrombosis in patients with gynecologic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Direct thrombin inhibitors: pharmacology and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2805%2980062-2

7 January 2021

10.1016/S1550-8579(05)80062-2

Identifiers

DOI

1 reference

14 August 2017

1 reference